Skip to main content
. 2024 Sep 9;47(11):3126–3146. doi: 10.1038/s41440-024-01865-7

Fig. 2.

Fig. 2

A Survival and (B) body weight (BW) changes in Ren-2 transgenic hypertensive rats (TGR) treated weekly with doxorubicin (DOXO) for 5 weeks in comparison to the control TGR (placebo-treated) group; ****P ≤ 0.0001 by log-rank Mantel-Cox (survival) and by 2-way ANOVA with repeated measures with Bonferroni’s multiple comparisons test (BW changes)